Summit Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Summit Therapeutics Inc in the third quarter 2026?
Summit Therapeutics Inc recorded a cumulative net loss of $-833 million during 12 months ending in the third quarter 2026, resulting in a negative return on equity (ROE) of -138.81%.

Within the Major Pharmaceutical Preparations industry 301 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 2105 to 3854.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	193.7 %	142.83 %	58.55 %	69.48 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-833	-856	-1,206	-1,080	-922
Return On Equity (TTM)	-138.81 %	-168.93 %	-291.24 %	-296.82 %	-311.15 %
SMMT's Total Ranking	# 3854	# 2105	# 2537	# 3470	#
Equity (TTM) in Millions	565	630	546	659	192
Seq. Equity Change	-10.37 %	15.4 %	-17.14 %	242.69 %	-25.89 %
Seq. Net Income Change	-	-	-	-	-

Back to SMMT Management Effectiveness >> SMMT's 5 Years Annual ROE >> Compare SMMT ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 302
Sector	# 645
Overall	# 3854

Return On Equity Statistics
High	Average	Low
18.91 %	-151.48 %	-571.82 %
(Dec 31 2019)		(Dec 31 2023)

News about Summit Therapeutics Inc Return on Equity ROE

Ivonescimab A Revolution in First-Line Treatment for Squamous Non-Small Cell Lung Cancer - Insights from the HARMONi-...

The treatment landscape for squamous non-small cell lung cancer (squamous NSCLC) has witnessed significant advancements with the introduction of novel therapeutic agents. The recent Phase III HARMONi-6 study conducted by Akeso, presented at the European Society for Medical Oncology (ESMO 2025) Congress, revealed that ivonescimab, a bispecific antibody, demonstrated a noteworthy reduction in the risk of disease progression or death by 40% when compared to tislelizumab, a PD-1 inhibitor, in combination with chemotherapy. This article aims to delve into the study s findings, discuss the implications for clinical practice, and offer insights into the evolving therapeutic landscape for patients with squamous NSCLC. Lung cancer remains one of the leading causes of cancer-related morbidity and mortality globally, with non-small cell lung cancer (NSCLC) representing a significant proportion of cases. Within NSCLC, squamous cell carcinoma accounts for approximately 25%-30% of all diagnoses. Conventional treatment options have included chemotherapy and immunotherapy; however, the quest for more effective therapies continues.

SMMT Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	659	389	78	127	83
Y / Y Equity Change	69.48 %	400.37 %	-38.66 %	52.07 %	4.82 %
Net Income in Millions	-1,080	-221	-615	-79	-89
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-163.86 %	-56.93 %	-791.49 %	-62.2 %	-106.39 %

Back to SMMT Management Effectiveness >> SMMT's 5 Years Annual ROE >> Compare SMMT ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SMMT's' Return on Equity at Yahoo Finance
SMMT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SMMT's Competitors
Subscribers only: Roe for Summit Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for SMMT's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector

ROE

Date modified: 2026-11-05T06:40:52+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.